PL3993876T3 - Przeciwciała anty-cd154 i ich zastosowania - Google Patents

Przeciwciała anty-cd154 i ich zastosowania

Info

Publication number: PL3993876T3
Authority: PL; Poland
Prior art keywords: antibodies
Prior art date: 2019-07-01

Application number

PL20764933.6T

Other languages

English (en)

Inventor

Seth Lederman

Original Assignee

Tonix Pharma Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-07-01

Filing date

2020-07-01

Publication date

2025-01-20

2020-07-01 Application filed by Tonix Pharma Limited filed Critical Tonix Pharma Limited

2025-01-20 Publication of PL3993876T3 publication Critical patent/PL3993876T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Transplantation (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL20764933.6T 2019-07-01 2020-07-01 Przeciwciała anty-cd154 i ich zastosowania PL3993876T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201962869489P	2019-07-01	2019-07-01
US202063018123P	2020-04-30	2020-04-30
PCT/EP2020/068589 WO2021001458A1 (en)	2019-07-01	2020-07-01	Anti-cd154 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
PL3993876T3 true PL3993876T3 (pl)	2025-01-20

Family

ID=72752868

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL20764933.6T PL3993876T3 (pl)	2019-07-01	2020-07-01	Przeciwciała anty-cd154 i ich zastosowania

Country Status (22)

Country	Link
US (1)	US20220380478A1 (pl)
EP (2)	EP3993876B1 (pl)
JP (2)	JP7775080B2 (pl)
CN (2)	CN120365423A (pl)
AU (1)	AU2020300002A1 (pl)
BR (1)	BR112021026410A2 (pl)
CA (1)	CA3145453A1 (pl)
DK (1)	DK3993876T3 (pl)
ES (1)	ES2994684T3 (pl)
FI (1)	FI3993876T3 (pl)
HR (1)	HRP20241602T1 (pl)
HU (1)	HUE069680T2 (pl)
IL (1)	IL289354A (pl)
LT (1)	LT3993876T (pl)
MX (1)	MX2022000133A (pl)
PL (1)	PL3993876T3 (pl)
PT (1)	PT3993876T (pl)
RS (1)	RS66218B1 (pl)
SI (1)	SI3993876T1 (pl)
SM (1)	SMT202400527T1 (pl)
WO (1)	WO2021001458A1 (pl)
ZA (1)	ZA202201378B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112021022682A2 (pt)	2019-05-14	2022-02-22	Provention Bio Inc	Métodos e composições para prevenir diabetes do tipo 1
MA54325A (fr)	2019-06-05	2022-05-11	Regeneron Pharma	Dispositifs et procédés pour l'administration précise de doses
CN111265528A (zh)	2020-01-21	2020-06-12	中国人民解放军军事科学院军事医学研究院	法匹拉韦在治疗冠状病毒感染方面的应用
US12006366B2 (en)	2020-06-11	2024-06-11	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
CN112778387A (zh) *	2021-01-15	2021-05-11	杭州科巢生物科技有限公司	一种Molnupiravir晶型A及其制备方法
CN116782946A (zh) *	2021-01-30	2023-09-19	百济神州有限公司	使用btk抑制剂治疗慢性活动性抗体介导的排斥的方法
WO2022251253A1 (en)	2021-05-24	2022-12-01	Provention Bio, Inc.	Methods for treating type 1 diabetes
EP4382537A4 (en) *	2021-07-30	2025-07-23	Seoul Nat Univ R&Db Foundation	ANTI-CD154 ANTIBODY AND ITS USE
WO2023008982A1 (ko) *	2021-07-30	2023-02-02	서울대학교산학협력단	항 cd154 항체 및 이의 용도
USD1120314S1 (en)	2022-11-30	2026-03-24	Regeneron Pharmaceuticals, Inc.	Dose delivery device
AU2024262779A1 (en) *	2023-04-28	2025-12-11	Fortvita Biologics Inc.	Anti-cd40l antibody and use thereof in treatment of human autoimmune diseases
US20240392022A1 (en) *	2023-05-22	2024-11-28	Genzyme Corporation	Treatment of multiple sclerosis with anti-cd40l antibodies
WO2025117849A1 (en)	2023-11-28	2025-06-05	Eledon Pharmaceuticals, Inc.	Methods and compositions for prevention of transplant rejection
WO2025217523A1 (en) *	2024-04-12	2025-10-16	23Andme, Inc.	Variant hinge and molecules comprising same
WO2025235683A1 (en)	2024-05-07	2025-11-13	Eledon Pharmaceuticals, Inc.	Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en)	2024-05-07	2025-11-13	Eledon Pharmaceuticals, Inc.	Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025248134A1 (en) *	2024-05-31	2025-12-04	Tonix Pharma Limited	Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de)	1985-04-01	1990-02-15	Celltech Ltd	Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
DE3617976A1 (de)	1986-05-28	1988-01-14	Alter Sa	1,4-dihydropyridin, verfahren zu dessen herstellung und dessen verwendung in antithrombotischen medikamenten
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6713610B1 (en)	1990-01-12	2004-03-30	Raju Kucherlapati	Human antibodies derived from immunized xenomice
US6657103B1 (en)	1990-01-12	2003-12-02	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US7041871B1 (en)	1995-10-10	2006-05-09	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ATE255131T1 (de)	1991-06-14	2003-12-15	Genentech Inc	Humanisierter heregulin antikörper
US7070777B1 (en)	1991-11-15	2006-07-04	The Trustees Of Columbia University In The City Of New York	Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en)	1991-11-15	1995-12-12	The Trustees Of Columbia University In The City Of New York	Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5492895A (en)	1992-02-14	1996-02-20	Corvas International, Inc.	Inhibitors of thrombosis
WO1994007918A1 (en)	1992-10-02	1994-04-14	Diatech, Inc.	Multimeric polyvalent antithrombotic agents
US5332822A (en)	1992-12-24	1994-07-26	Bristol-Myers Squibb Company	Heteroaromatic and thioheteroaromatic substituted sulfonamide thrombin inhibitors
IL115420A0 (en)	1994-09-26	1995-12-31	Zeneca Ltd	Aminoheterocyclic derivatives
WO1996017078A1 (en)	1994-11-30	1996-06-06	Ajinomoto Co., Inc.	Antithrombotic agent and anti-von willebrand factor monoclonal antibodies
DE69630214T2 (de)	1995-03-10	2004-07-15	Berlex Laboratories, Inc., Richmond	Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
US5612363A (en)	1995-06-02	1997-03-18	Berlex Laboratories, Inc.	N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US5721214A (en)	1995-06-07	1998-02-24	Cor Therapeutics, Inc.	Inhibitors of factor Xa
US6340459B1 (en)	1995-12-01	2002-01-22	The Trustees Of Columbia University In The City Of New York	Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US5849759A (en)	1995-12-08	1998-12-15	Berlex Laboratories, Inc.	Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5741779A (en)	1996-05-10	1998-04-21	Xoma Corporation	Antithrombotic materials and methods
US5753635A (en)	1996-08-16	1998-05-19	Berlex Laboratories, Inc.	Purine derivatives and their use as anti-coagulants
US5693641A (en)	1996-08-16	1997-12-02	Berlex Laboratories Inc.	Bicyclic pyrimidine derivatives and their use as anti-coagulants
US5933816A (en)	1996-10-31	1999-08-03	Citicorp Development Center, Inc.	System and method for delivering financial services
UA56197C2 (uk)	1996-11-08	2003-05-15	Зенека Лімітед	Гетероциклічні похідні
IT1295694B1 (it)	1996-11-14	1999-05-27	Nicox Sa	Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
ATE549918T1 (de)	1996-12-03	2012-04-15	Amgen Fremont Inc	Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
AUPO556297A0 (en)	1997-03-11	1997-04-10	Australian National University, The	Sulfated oligosaccharides having anticoagulant/ antithrombotic activity
IL123986A (en)	1997-04-24	2011-10-31	Organon Nv	Medicinal compounds
US6313151B1 (en)	1997-06-26	2001-11-06	Eli Lilly And Company	Antithrombotic agents
DE19727117A1 (de)	1997-06-26	1999-01-07	Boehringer Ingelheim Pharma	Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9715894D0 (en)	1997-07-29	1997-10-01	Zeneca Ltd	Heterocyclic derivatives
US6140351A (en)	1997-12-19	2000-10-31	Berlex Laboratories, Inc.	Ortho-anthranilamide derivatives as anti-coagulants
US6242195B1 (en)	1998-04-02	2001-06-05	Genentech, Inc.	Methods for determining binding of an analyte to a receptor
US6200976B1 (en)	1998-04-17	2001-03-13	Boehringer Ingelheim Pharma Kg	Antithrombotic quinoxazolines
AU754453B2 (en)	1998-05-02	2002-11-14	Astrazeneca Ab	Heterocyclic derivatives which inhibit factor Xa
GB9809349D0 (en)	1998-05-02	1998-07-01	Zeneca Ltd	Heterocyclic derivatives
WO1999065934A1 (en)	1998-06-17	1999-12-23	Akzo Nobel N.V.	Antithrombotic compounds
US6248770B1 (en)	1998-07-09	2001-06-19	Boehringer Ingelheim Pharma Kg	Benzimidazoles having antithrombotic activity
FR2781223B1 (fr)	1998-07-17	2000-10-13	Lafon Labor	Bispiperidines et leurs applications therapeutiques
DK0997474T3 (da)	1998-08-14	2004-02-09	Pfizer	Antithrombotiske midler
EP0987274A1 (en)	1998-09-15	2000-03-22	Hoechst Marion Roussel Deutschland GmbH	Factor VIIa Inhibitors
GB9902989D0 (en)	1999-02-11	1999-03-31	Zeneca Ltd	Heterocyclic derivatives
EP1059302A1 (en)	1999-06-08	2000-12-13	Aventis Pharma Deutschland GmbH	Factor VIIa inhibitors
US6417203B1 (en)	1999-08-11	2002-07-09	Pfizer Inc.	Antithrombotic agents
US6849425B1 (en)	1999-10-14	2005-02-01	Ixsys, Inc.	Methods of optimizing antibody variable region binding affinity
US6517529B1 (en)	1999-11-24	2003-02-11	Radius International Limited Partnership	Hemodialysis catheter
US6451832B2 (en)	1999-12-23	2002-09-17	Boehringer Ingelheim Pharma Kg	Benzimidazoles with antithrombotic activity
AU2001282871A1 (en)	2000-08-17	2002-02-25	Eli Lilly And Company	Antithrombotic agents
US6586251B2 (en)	2000-10-31	2003-07-01	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US6774110B2 (en)	2001-03-19	2004-08-10	Lg Life Sciences Ltd.	Orally available peptidic thrombin inhibitors
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
DE602004029252D1 (de) *	2003-06-13	2010-11-04	Biogen Idec Inc	Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
CN1871259A (zh)	2003-08-22	2006-11-29	比奥根艾迪克Ma公司	具有改变的效应物功能的经改进的抗体和制备它的方法
CZ200755A3 (cs)	2004-07-26	2007-04-11	Biogen Idec Ma Inc.	Peptidy protilátek anti-CD154
EP1943332A4 (en)	2005-10-14	2011-04-13	Medimmune Inc	CELLULAR DISPLAY OF ANTIBODY LIBRARIES
JP5514539B2 (ja)	2006-03-31	2014-06-04	メダレックス・リミテッド・ライアビリティ・カンパニー	ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
SG196697A1 (en) *	2007-03-22	2014-02-13	Biogen Idec Inc	Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
GB0815788D0 (en) *	2008-08-29	2008-10-08	Isis Innovation	Therapeutic antibodies
BRPI1006998A2 (pt) *	2009-01-23	2015-08-25	Biogen Idec Inc	Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
PL3053932T3 (pl)	2010-02-19	2021-03-08	Xencor, Inc.	Nowe immunoadhezyny CTLA4-IG
PL2635607T3 (pl)	2010-11-05	2020-05-18	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
AR083847A1 (es) *	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2692268T5 (en) *	2011-03-29	2025-02-26	Roche Glycart Ag	Antibody fc variants
WO2012138768A2 (en) *	2011-04-04	2012-10-11	Trustees Of Dartmouth College	Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
SMT202000091T1 (it) *	2011-10-13	2020-05-08	Bristol Myers Squibb Co	Polipeptidi anticorpali che antagonizzano cd40l
WO2015143209A1 (en) *	2014-03-19	2015-09-24	Bristol-Myers Squibb Company	Methods of treating transplant rejection using a domain antibody directed against cd40l
MA41459A (fr) *	2015-02-03	2017-12-12	Als Therapy Development Inst	Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890434A1 (ru) *	2015-08-05	2018-10-31	Янссен Байотек, Инк.	Антитела к cd154 и способы их применения
CN109153727A (zh)	2016-04-15	2019-01-04	酵活有限公司	靶向免疫治疗剂的多特异性抗原结合构建体
MA45919A (fr) *	2016-08-12	2019-06-19	Janssen Biotech Inc	Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
WO2018032638A1 (zh) *	2016-08-19	2018-02-22	安源医药科技（上海）有限公司	用于构建融合蛋白的连接肽
SG10202111207TA (en) *	2017-05-24	2021-11-29	Als Therapy Development Inst	Therapeutic anti-cd40 ligand antibodies
KR20200018781A (ko) *	2017-06-19	2020-02-20	스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘)	반감기 연장 폴리펩티드를 갖는 융합 단백질
KR102757960B1 (ko) *	2017-06-26	2025-01-22	베이진 엘티디	간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료

2020
- 2020-07-01 BR BR112021026410A patent/BR112021026410A2/pt unknown
- 2020-07-01 LT LTEPPCT/EP2020/068589T patent/LT3993876T/lt unknown
- 2020-07-01 US US17/623,710 patent/US20220380478A1/en active Pending
- 2020-07-01 FI FIEP20764933.6T patent/FI3993876T3/fi active
- 2020-07-01 HR HRP20241602TT patent/HRP20241602T1/hr unknown
- 2020-07-01 SI SI202030541T patent/SI3993876T1/sl unknown
- 2020-07-01 HU HUE20764933A patent/HUE069680T2/hu unknown
- 2020-07-01 ES ES20764933T patent/ES2994684T3/es active Active
- 2020-07-01 PL PL20764933.6T patent/PL3993876T3/pl unknown
- 2020-07-01 MX MX2022000133A patent/MX2022000133A/es unknown
- 2020-07-01 CN CN202510443183.2A patent/CN120365423A/zh active Pending
- 2020-07-01 JP JP2021578262A patent/JP7775080B2/ja active Active
- 2020-07-01 PT PT207649336T patent/PT3993876T/pt unknown
- 2020-07-01 CN CN202080059891.1A patent/CN114423785B/zh active Active
- 2020-07-01 WO PCT/EP2020/068589 patent/WO2021001458A1/en not_active Ceased
- 2020-07-01 EP EP20764933.6A patent/EP3993876B1/en active Active
- 2020-07-01 AU AU2020300002A patent/AU2020300002A1/en active Pending
- 2020-07-01 SM SM20240527T patent/SMT202400527T1/it unknown
- 2020-07-01 EP EP24195755.4A patent/EP4491193A3/en active Pending
- 2020-07-01 DK DK20764933.6T patent/DK3993876T3/da active
- 2020-07-01 CA CA3145453A patent/CA3145453A1/en active Pending
- 2020-07-01 RS RS20241312A patent/RS66218B1/sr unknown
2021
- 2021-12-23 IL IL289354A patent/IL289354A/en unknown
2022
- 2022-01-28 ZA ZA2022/01378A patent/ZA202201378B/en unknown
2025
- 2025-06-11 JP JP2025097959A patent/JP2025123314A/ja active Pending

Also Published As

Publication number	Publication date
SMT202400527T1 (it)	2025-01-14
EP3993876B1 (en)	2024-08-28
AU2020300002A1 (en)	2022-02-24
JP2022538674A (ja)	2022-09-05
EP3993876A1 (en)	2022-05-11
JP7775080B2 (ja)	2025-11-25
EP4491193A2 (en)	2025-01-15
PT3993876T (pt)	2024-11-21
IL289354A (en)	2022-02-01
RS66218B1 (sr)	2024-12-31
DK3993876T3 (en)	2024-12-02
WO2021001458A1 (en)	2021-01-07
CN120365423A (zh)	2025-07-25
LT3993876T (lt)	2024-11-11
HUE069680T2 (hu)	2025-04-28
EP4491193A3 (en)	2025-04-30
MX2022000133A (es)	2022-04-27
FI3993876T3 (fi)	2024-11-28
CN114423785B (zh)	2025-04-22
JP2025123314A (ja)	2025-08-22
BR112021026410A2 (pt)	2022-02-08
CN114423785A (zh)	2022-04-29
ES2994684T3 (en)	2025-01-29
SI3993876T1 (sl)	2025-02-28
CA3145453A1 (en)	2021-01-07
US20220380478A1 (en)	2022-12-01
ZA202201378B (en)	2025-10-29
HRP20241602T1 (hr)	2025-01-31

Publication	Publication Date	Title
DK3993876T3 (en)	2024-12-02	Anti-cd154 antibodies and uses thereof
IL282968A (en)	2021-06-30	Anti-NKG2A antibodies and their use
IL276950A (en)	2020-10-29	Anti-CD73 antibodies and uses thereof
SG11202105885WA (en)	2021-07-29	Anti-claudin antibodies and uses thereof
IL277308A (en)	2020-10-29	Antibodies against HLA-G and their use
IL289585A (en)	2022-03-01	DLL3-targeted antibodies and uses thereof
IL275826A (en)	2020-08-31	Anti-mct1 antibodies and their uses
SG11202008390SA (en)	2020-09-29	Antibodies that bind cd39 and uses thereof
IL291027A (en)	2022-05-01	Anti-steap1 antibodies and uses thereof
IL280321A (en)	2021-03-01	Antibodies against CXCR2 and their uses
SG11202009772PA (en)	2020-11-27	Anti-dll3 antibodies and uses thereof
IL289656A (en)	2022-03-01	Anti-tigit antibodies and their application
IL281202A (en)	2021-04-29	Anti-TNFRSF9 antibodies and uses thereof
ZA202100714B (en)	2023-07-26	Anti-npr1 antibodies and uses thereof
IL277075A (en)	2020-10-29	Anti-PHF-tau antibodies and uses thereof
SG11202009625WA (en)	2020-10-29	Anti-trem-1 antibodies and uses thereof
SG11202105161YA (en)	2021-06-29	Anti-il-27 antibodies and uses thereof
IL277330A (en)	2020-10-29	Anti-IL-27 antibodies and uses thereof
IL276548A (en)	2020-09-30	Binding antibodies - BCMA and their uses
HRP20260007T1 (hr)	2026-03-13	Humanizirano antitijelo protiv il17a i njegova uporaba
SG11202012680TA (en)	2021-01-28	Anti-l1cam antibodies and uses thereof
IL283926B1 (en)	2026-05-01	Antibodies against alpha-synuclein and their uses
IL283890A (en)	2021-07-29	Anti-periostin antibodies and their uses
ZA202210284B (en)	2023-03-29	Anti-trem1 antibodies and related methods
GB201902590D0 (en)	2019-04-10	Antibodies and uses thereof